BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qureshi K, Patel S, Meillier A. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence. Int J Hepatol 2016;2016:1802932. [PMID: 27800187 DOI: 10.1155/2016/1802932] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Lisman T, Porte RJ. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. Res Pract Thromb Haemost 2017;1:150-61. [PMID: 30046685 DOI: 10.1002/rth2.12028] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
2 Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol 2020;2020:5421632. [PMID: 32047671 DOI: 10.1155/2020/5421632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, Gejima K, Komokata T, Hashiguchi T, Imoto Y. Therapeutic implication of platelets in liver regeneration -hopes and hues. Expert Rev Gastroenterol Hepatol. 2018;12:1219-1228. [PMID: 30791793 DOI: 10.1080/17474124.2018.1533813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Um J, Lee JH, Jung DW, Williams DR. Re-education begins at home: an overview of the discovery of in vivo-active small molecule modulators of endogenous stem cells. Expert Opin Drug Discov 2018;13:307-26. [PMID: 29421943 DOI: 10.1080/17460441.2018.1437140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Shirley M. Avatrombopag: First Global Approval. Drugs 2018;78:1163-8. [PMID: 29995177 DOI: 10.1007/s40265-018-0949-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
6 Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, Makara M, Ben Ari Z, Braun M, Mitrut P, Yang SS, Akdogan M, Pirisi M, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Afdhal N. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019;70:1336-1348. [PMID: 30762895 DOI: 10.1002/hep.30561] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
7 Roy S. Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever? Cureus 2019;11:e4361. [PMID: 31192066 DOI: 10.7759/cureus.4361] [Reference Citation Analysis]
8 Zakeri N, Tsochatzis EA. Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Curr Gastroenterol Rep. 2017;19:45. [PMID: 28752476 DOI: 10.1007/s11894-017-0585-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
9 Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. J Clin Gastroenterol 2020;54:503-11. [PMID: 32195771 DOI: 10.1097/MCG.0000000000001338] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nomoto M, Ferry J, Hussein Z. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors. J Clin Pharmacol 2018;58:1629-38. [PMID: 29905956 DOI: 10.1002/jcph.1267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Miki N, Inoue S, Shibahara H, Kurazono K, Perard R, Tateishi R. A cost-effectiveness analysis of lusutrombopag for thrombocytopenia in patients with chronic liver disease in Japan. JGH Open 2021;5:879-87. [PMID: 34386595 DOI: 10.1002/jgh3.12597] [Reference Citation Analysis]
12 Vizio B, Bosco O, David E, Caviglia GP, Abate ML, Schiavello M, Pucci A, Smedile A, Paraluppi G, Romagnoli R, Lupia E, Bellone G, Montrucchio G. Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma. Int J Mol Sci 2021;22:1818. [PMID: 33673041 DOI: 10.3390/ijms22041818] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Jia Z, Gong Y, Pi Y, Liu X, Gao L, Kang L, Wang J, Yang F, Tang J, Lu W, Li Q, Zhang W, Yan Z, Yu L. pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis. Mol Pharm 2018;15:53-62. [PMID: 29148802 DOI: 10.1021/acs.molpharmaceut.7b00709] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
14 Elsaid MI, Rustgi VK, Loo N, Aggarwal K, Li-mcleod J, Niu X, Poordad F. The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease. Journal of Medical Economics 2020;23:378-85. [DOI: 10.1080/13696998.2019.1699563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]